- Sight Sciences Inc (NASDAQ: SGHT) announced 36-month post-surgery follow-up results of the OMNI Surgical System.
- The data demonstrates that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis.
- The study showed that canaloplasty followed by trabeculectomy using the OMNI Surgical System achieved a mean reduction in intraocular pressure (IOP) of at least 20% for all 26 patients (38 eyes) at 36 months follow-up.
- The post-operative IOP and medication use reduction at 12 months remained consistent over three years, suggesting robust, durable effectiveness of the OMNI Surgical System.
- A minimal number of adverse events were reported, all resolved without intervention except one eye required secondary IOP lowering intervention.
- Price Action: SGHT shares are down 2.86% at $8.51 during the market session on the last check Tuesday.
What’s Going On With Marker Therapeutics (MRKR) Stock
Marker Therapeutics, Inc. (NASDAQ: MRKR) shares are trading higher by 3.0% to $5.50 Tuesday morning.
